disease in those who develop renal failure is fairly well understood. Early nephropathy can be identified by a simple urine test and the course of disease can be modified by both drug and non-drug intervention. So should we systematically screen the diabetic population to reduce the incidence of renal failure?
The disease The incidence of renal failure in diabetes is not known, but in 1985 and 1986 there were 3753 death certificates from England and Wales which mentioned diabetes with renal failure. Diabetes is now the single commonest diagnosis in new dialysis patients in the USA2 and accounts for a rapidly increasing proportion of those receiving replacement therapy in most European countries.3 This should not be taken to mean that the incidence of diabetic nephropathy is rising, since acceptance of diabetic patients for renal replacement therapy undoubtedly reflects availability of treatment and medical attitudes to patient suitability. In the USA, the cost of treatment for diabetic end stage renal disease has been estimated at $1 8 billion each year and is rising rapidly. Although renal failure occurs in both insulin dependent and non-insulin-dependent diabetes, most of the available data is about insulin dependent diabetes (IDDM) to which the following applies. 100%, and that of a negative test from 96% to 100%. Given that intraindividual variation in urinary albumin excretion is high, the test characteristics calculated in these studies look promising. However, these studies did not take account of duration of diabetes and glycaemic control, which are major risk factors for diabetic nephropathy. In three ofthe studies,5-7 the differences in mean duration of diabetes between positively screened (14, 17, and 19 years) and negatively screened patients (9, 13, and 15 years respectively) span the period when the incidence of proteinuria rises most steeply with duration. Further questions about the predictive value of urinary albumin excretion are raised by two large cross sectional studies, which show that the prevalence of microalbuminuria continues to rise after more than 30 years of diabetes. Since the incidence of nephropathy declines markedly after 25-30 years, these findings imply that progression from microalbuminuria to proteinuria may not be the rule, at least in people with longstanding disease. Longitudinal studies which take account of confounding factors are needed to determine more precisely the risk of progression to clinical nephropathy at different levels of urinary albumin excretion.
Measurement of the rate of urinary albumin excretion requires a timed urine collection, but there is good correlation between overnight albumin/creatinine ratio and albumin excretion, and "microalbuminuria detecting dipsticks" are becoming available for use on 
